---

Clinical Differential Diagnosis of Uterine/Endometrial Conditions - Pathological Basis

---

1. ENDOMETRIOSIS

Pathological Definition

Gross Pathology

• Superficial implants: Red/blue/black "powder-burn" lesions on peritoneal surfaces
• Ovarian endometrioma: "Chocolate cyst" - cyst filled with old hemorrhagic material resembling chocolate syrup; wall contains endometrial glands and stroma
• Deep infiltrating: Firm, fibrotic nodules in rectovaginal septum, uterosacral ligaments; can invade rectum, bladder
• Repeated cyclic hemorrhage leads to dense fibrous adhesions that distort pelvic anatomy

Microscopic Pathology

• Ectopic foci contain all three components of functional endometrium: glands, stroma, and hemosiderin-laden macrophages (diagnostic triad)
• Glands respond to hormonal stimulation (proliferative/secretory changes)
• Surrounding fibrosis and hemosiderin deposition (siderophages)
• Stroma has characteristic small, dark stromal cells with scanty cytoplasm
• In old lesions, glands may be obliterated leaving only stroma + hemosiderin
• Malignant transformation: rare (~1%), mainly in ovarian endometriosis -> endometrioid or clear cell carcinoma

Molecular/Pathogenesis

• Elevated aromatase -> local estrogen production
• Increased prostaglandin E2, VEGF, MMPs
• Progesterone resistance at the stromal cell level
• Retrograde menstruation + immune failure to clear implants

Clinical Correlation

• Affects reproductive-age women (20s-30s)
• Classic triad: dysmenorrhea, dyspareunia, infertility ("3 Ds" + infertility)
• Symptoms cyclically worse with menstruation
• CA-125 may be mildly elevated

---

2. ADENOMYOSIS

Pathological Definition

Gross Pathology

• Uterus is symmetrically, diffusely enlarged (globular uterus) - may reach 200-300g (normal ~70g)
• Cut surface: thickened uterine wall, trabeculated myometrium; small hemorrhagic cystic spaces may be visible (corresponding to ectopic glands)
• No discrete fibroid nodule (unlike leiomyoma)
• Poorly circumscribed - key differentiating feature from leiomyoma

Microscopic Pathology

• Endometrial islands (glands + stroma) deep within myometrium, interposed between muscle bundles
• Islands are typically basalis-type endometrium - do NOT respond to cyclical hormonal changes (unlike eutopic endometrium)
• Surrounding smooth muscle shows reactive hypertrophy
• May coexist with endometriosis (~15% of cases)

Molecular/Pathogenesis

• Thought to arise from direct invagination of the basal endometrium into myometrium (invasion theory)
• Associated with increased uterine peristalsis and trauma (multiparity, prior uterine surgery)
• Estrogen-dependent (regresses after menopause)

Clinical Correlation

• Affects multiparous women in late reproductive years (35-50)
• Classic: secondary dysmenorrhea, menorrhagia, symmetrically enlarged tender uterus
• Uterus is soft and boggy - "always bigger before menstruation and smaller after"
• Definitive diagnosis only on hysterectomy specimen

---

3. ENDOMETRIAL HYPERPLASIA

Pathological Definition

WHO Classification (Two Major Types)

Gross Pathology

• Thickened, velvety, spongy endometrium
• Polypoidal projections may be present
• Proliferative type: pale, white-tan thickened mucosa
• No myometrial invasion

Microscopic Pathology

• Without atypia: increased G:S ratio, dilated cystic glands, back-to-back glands - NO cytologic atypia
• With atypia (EIN): glandular crowding, nuclear enlargement, round/vesicular nuclei, prominent nucleoli, loss of polarity; may have confluent glandular growth approaching carcinoma
• Stroma is compressed but present between glands (in contrast to carcinoma where stroma is replaced)

Molecular Pathogenesis

• PTEN inactivation is the earliest molecular event - found in >20% of both subtypes
• PI3K/AKT pathway overactivation
• Microsatellite instability in some cases (MLH1 promoter methylation)
• Lynch syndrome (germline MMR gene mutation) -> high lifetime risk
• Cowden syndrome (germline PTEN mutation) -> high risk of both endometrial hyperplasia and carcinoma

Clinical Correlation

• Perimenopausal women (45-55)
• Presents with abnormal uterine bleeding (irregular, intermenstrual, postmenopausal)
• Associated with obesity, PCOS, unopposed estrogen therapy, granulosa cell tumors
• Diagnosed by endometrial biopsy / D&C

---

4. ENDOMETRIAL CARCINOMA

Pathological Definition

TYPE I - Endometrioid Carcinoma (80%)

Gross Pathology

• Exophytic, polypoid or infiltrative mass in endometrial cavity
• Gray-white, friable, necrotic
• Myometrial invasion - depth determines staging (confined to endometrium = stage IA; >50% myometrium = stage IB)
• May extend to cervix (stage II), adnexa, parametrium (stage III)

Microscopic Pathology

• Well-differentiated (grade 1): closely mimics proliferative endometrium; back-to-back tubular glands with minimal stroma; <5% solid growth
• Grade 2: 6-50% solid growth; increasing atypia
• Grade 3: >50% solid growth; marked nuclear atypia, large nucleoli
• Myometrial invasion: irregular infiltrating glands with desmoplastic stroma - key feature
• Squamous differentiation may occur (adenoacanthoma = benign squames; adenosquamous = malignant squames)
• Immunostaining: ER+, PR+, vimentin+; p53 usually wild-type pattern

Molecular Pathogenesis

• PTEN mutations (early event, 30-80%)
• MMR gene mutations (MSI-H subtype)
• PIK3CA mutations
• KRAS, CTNNB1 (beta-catenin) mutations
• Arises in background of endometrial hyperplasia with atypia (EIN)
• Associated with Lynch syndrome (MLH1, MSH2 mutations)

TYPE II - Serous Carcinoma (15%)

Gross Pathology

• Often arises on atrophic endometrium (no preceding hyperplasia)
• Small primary tumor but early peritoneal spread
• Papillary/exophytic growth

Microscopic Pathology

• Small papillary tufts with complex branching; marked cytologic atypia
• Hobnail cells, slit-like glandular spaces
• High-grade by definition - marked nuclear pleomorphism, macronucleoli
• Psammoma bodies in ~30%
• Precursor lesion: Serous Endometrial Intraepithelial Carcinoma (SEIC) - morphologically malignant cells on atrophic endometrium
• IHC: diffuse/strong p53+ (mutant pattern), WT1 often positive; ER/PR negative

Molecular Pathogenesis

• TP53 mutation in nearly ALL cases (early event)
• PTEN and MMR mutations rare
• HER2 amplification in ~30%
• Overlap with high-grade serous ovarian carcinoma
• Associated with BRCA mutations

Clinical Correlation

• Endometrioid: postmenopausal obese women, 55-65 years; risk factors = obesity, nulliparity, diabetes, HRT (unopposed estrogen), tamoxifen use
• Serous: older, postmenopausal, 65-70 years; NOT associated with obesity/estrogen
• Both present with postmenopausal bleeding (endometrial biopsy is gold standard)
• Grade 1 endometrioid: 5-year survival ~90%; serous: poor prognosis due to advanced stage at presentation

---

5. ENDOMETRIAL STROMAL TUMOR

Pathological Definition

Classification

Gross Pathology

• Stromal nodule: discrete, well-circumscribed, yellow-tan, soft nodule in myometrium
• LG-ESS: worm-like plugs of tumor extending into myometrial vessels and lymphatics - classic "Indian filing" pattern; cut surface shows yellow-tan bands permeating myometrium; ill-defined borders
• HG-ESS/UUS: large fleshy hemorrhagic mass, necrosis

Microscopic Pathology

• Stromal nodule and LG-ESS: uniform, small cells resembling proliferative-phase stromal cells - oval nuclei, scant cytoplasm, spiral arteriole-like vasculature (tongue-like projections into myometrium in LG-ESS)
• LG-ESS: infiltrating margins with perivascular spread; low mitotic rate (<10/10 HPF); CD10+, ER+, PR+
• HG-ESS: high-grade round to spindle cells, >10 mitoses/10 HPF; YWHAE-NUTM2 gene fusion; CD10 negative; cyclin D1 overexpression
• UUS: pleomorphic, undifferentiated cells; no specific markers; diagnosis of exclusion

Molecular Pathogenesis

• LG-ESS: JAZF1-SUZ12 fusion (most common, ~50%); PHF1-JAZF1 fusions also described
• HG-ESS: YWHAE-NUTM2A/B fusion
• CD10 expression reflects stromal origin

Clinical Correlation

• Women in reproductive/perimenopausal age
• Presents with abnormal uterine bleeding and pelvic pain; often found incidentally
• LG-ESS: excellent prognosis with surgery; late recurrences after 5-10 years are characteristic; hormone-responsive (ER/PR+), responds to progestins/aromatase inhibitors
• HG-ESS/UUS: aggressive, rapid progression

---

6. UTERINE LEIOMYOMA (FIBROID)

Pathological Definition

Gross Pathology

• Multiple (vs. single) in most cases
• Sharply circumscribed, firm, gray-white nodules with classic whorled cut surface
• Well-delineated from surrounding myometrium (pseudocapsule)
• Locations:
  • Intramural (most common, within myometrium)
  • Submucosal (beneath endometrium - most symptomatic; cause AUB)
  • Subserosal (below serosa; may be pedunculated)
  • Cervical, broad ligament, parasitic (rare)
• Size: millimeters to 20+ cm
• Secondary changes (degeneration):
  • Hyaline degeneration (most common) - white, homogeneous areas
  • Cystic degeneration - central liquefaction
  • Red/carneous degeneration - hemorrhagic infarction (especially during pregnancy) - clinically presents as acute pain
  • Calcification ("womb stone") - in postmenopausal women
  • Myxoid degeneration

Microscopic Pathology

• Interlacing bundles of uniform, bland smooth muscle cells - cigar-shaped nuclei, eosinophilic cytoplasm, no nuclear atypia
• Low mitotic rate (<5 mitoses/10 HPF)
• Hyalinized collagen between muscle bundles (in degenerating areas)
• Absence of tumor cell necrosis
• IHC: SMA+, desmin+, h-caldesmon+
• Key distinction from leiomyosarcoma: leiomyosarcoma has nuclear atypia, >10 mitoses/10 HPF, and coagulative tumor cell necrosis ("Stanford criteria")

Molecular Pathogenesis

• MED12 mutations in up to 70% (encodes RNA pol II transcription regulator)
• Chromosomal rearrangements (6p21, 12q15 - HMGA2)
• Estrogen receptor and progesterone receptor positive (hormone-dependent growth)
• Shrink after menopause; grow rapidly in pregnancy
• Recurrent chromosomal rearrangements similar to lipomas and endometrial polyps

Clinical Correlation

• Women of reproductive age (30s-40s), more common in African-American women
• May be asymptomatic (found incidentally on USS)
• Symptomatic: menorrhagia (submucosal), pelvic pressure/bulk symptoms (large intramural/subserosal), urinary frequency/retention, dysmenorrhea
• Infertility if submucosal or distorting cavity
• Uterus: irregularly enlarged, firm, non-tender (unless red degeneration)

---

Summary Comparison Table

---

Key Pathological Differentiating Points

---

---

Differential Diagnosis: Breast Conditions - Clinical Features & Pathology

---

TABLE 1: CLINICAL FEATURES

---

TABLE 2: GROSS PATHOLOGY

---

TABLE 3: MICROSCOPIC (HISTOLOGICAL) PATHOLOGY

---

TABLE 4: MOLECULAR / IHC / PATHOGENESIS

---

TABLE 5: QUICK-REFERENCE SUMMARY (Key Distinguishing Features)

---

---

CLINICAL DECISION FLOWCHART: BREAST LESION DIAGNOSIS

                        BREAST LESION / COMPLAINT
                               |
          ┌────────────────────┼──────────────────────┐
          ▼                    ▼                       ▼
  Nipple/Areola          Breast Lump/Mass         Bilateral Tender
  Skin Change                                     Nodularity + Cyclic
  (eczematoid,                                    Pain / Mastalgia
  weeping, crusting)                                    │
          │                                             ▼
          ▼                                    FIBROCYSTIC DISEASE
  Punch Biopsy Nipple                         Reassure + analgesia
          │                                   Mammography follow-up
          ▼
  Paget cells? (CK7+, HER2+,
  large pale intraepidermal
  vacuolated cells)
          │
    YES ──┤
          ▼
  PAGET'S DISEASE OF BREAST
  → Bilateral Mammography
  → Palpable mass?
    - NO: Underlying DCIS → BCS + RT
    - YES: Underlying Invasive Ca → Staging + MDT

---

              BREAST LUMP - TRIPLE ASSESSMENT
        (Clinical + Imaging + Histopathology)
                          │
         ┌────────────────┼────────────────┐
         ▼                ▼                ▼
      Age 15-25         Age 25-50       Age >50 / PMB

         │                │                │
         ▼                ▼                ▼
    Ultrasound       Triple Assessment   Mammogram
    (preferred        (MMG + USS +       (spiculated
    over MMG in       core biopsy)       mass /
    young women)                         microcalcifications?)
         │                │                │
         ▼                ▼                ▼
   Well-defined,    Large, bosselated,   Hard, irregular,
   smooth,          rapidly growing,     fixed, painless
   homogeneous      mobile mass          mass
   oval mass?
         │                │                │
    FNAC/Core          Core Biopsy       Core Needle Biopsy
    Biopsy                │              (MANDATORY)
         │                │                │
         ▼                ▼                ▼
   Bland biphasic    Hypercellular     Invasive carcinoma
   proliferation,    stroma, leaf-     (broken BM,
   pushing margins,  like fronds,      desmoplastic stroma,
   MED12 mutation    mitoses counted   infiltrating glands)
         │                │                │
         ▼                ▼                ▼
   FIBROADENOMA      PHYLLODES TUMOR   BREAST CARCINOMA
         │                │                │
    <3 cm: observe   Grade:            IHC: ER / PR / HER2
    >3 cm: excise    Benign (<4/HPF)          │
    Giant: enucleate Border (4-9/HPF)   ┌────┴─────────┐
    Complex + FHx:   Malignant(>10/HPF) │              │
    close follow-up        │          Luminal      HER2 / TNBC
                           ▼            │              │
                  WLE (2 cm margin)   Endocrine    Chemo ±
                  NO axillary LN      therapy +    Targeted
                  dissection          surgery      therapy
                  Malignant: monitor              + surgery
                  for hematogenous mets

---

Key Rule - Triple Assessment

Concordance of all three = definitive diagnosis. Discordance = repeat biopsy / excision.